Webinar: Radionuclide Diagnostics & Theranostics – Theory and Clinical Practice Meet!
Nuclear payloads, guided missiles, directed assassinations…not in global conflict or wars, but prostate cancer and what happens inside bodies of men getting radionuclide theranostics (treatment) and diagnostics (scanning) today.
Radionuclide treatment for prostate cancer is at least 10 years old – does that surprise you? Bayer’s Xofigo was approved in 2013 but adoption has been slow until recent FDA approvals of theranostics (treatment) viz. Pluvicto, and diagnostics (scans) like Illucix and Posluma.
Radionuclides are theory-intense with nuclear medicine doctors less exposed to treatment of advanced prostate cancer. Conversely, GU medical oncologists are less familiar with radionuclides than hormone and chemo-therapy.
Two global experts, GU medical oncologist Dr. Oliver Sartor and nuclear medicine guru, Dr. Philip Kuo will introduce radionuclide theranostics and diagnostics and discuss how the clinic and the theory intersect.
Learn about radionuclide medicine – how it works and what it can do for you! This information will help patients learn how to make sure your Genitourinary Medical Oncologist and Nuclear Medicine Doctor work in harmony.
Watch here:
Special thanks to our sponsors who made this webinar possible….
For those that have been around AnCan for a while, the name Lindsey Byrne should be familiar. Lindsey is a Genetic Counselor at The Ohio State University (James) Comprehensive Cancer Center who specializes in prostate cancer. Click this link, and you’ll see everything she has done with AnCan!
Lindsey recently participated with Janssen Biotech, soon to be referred to as just Johnson & Johnson (JnJ), to make 3 short videos on the implications of the BRCA gene mutation for prostate cancer. This is part of a non-branded education effort as JnJ introduces its newly approved single pill, AKEEGA, that combines PARP-Inhibitor niraparib with ARSI, abiraterone acetate. Lindsey doesn’t just talk the talk; she walks the walk – ask her patient, frequent AnCan participant, Frank Fabish pictured together right. AnCan, btw, is also indirectly connected to panelist GU med onc Cora Sternberg, who went to grade school with one of our gents, and was a good family friend of another.
If the video seems a little stiff, that’s because it has to be fully scripted to meet FDA requirements for the manufacturers. That said, the information is good, understandable and accurate – although it may leave out important additional information AnCan would impart. So if you know very little about BRCA, and want to understand it better, we recommend watching these 3 short videos that you can do in les than 20 minutes. Clickhttps://www.uncoverbrca.com/expert-video-series/index.html
Two short caveats:
even if you don’t have prostate cancer, but your condition has a risk for BRCA mutations, the videos may be helpful. PARP-Inhibitors alone are often a treatment option when BRCA is present in any cancer.
in full disclosure, JnJ is a significant AnCan financial sponsor. However, JnJ neither requested nor required us to promote these videos.
Active Surveillance Prostate Cancer Virtual Support Group
Active Surveillance (AS) for low-risk prostate cancer presents its own challenges that are very different from other treatment protocols. This virtual group is for men and caregivers on or considering AS to treat their condition. New participants are given priority to discuss their situation.
1st, 2nd & 3rd Wednesdays & 4th Thursdays of each month at 8 pm EST/EDT (US)
Active Surveillance Prostate Cancer Virtual Support Group
Active Surveillance (AS) for low-risk prostate cancer presents its own challenges that are very different from other treatment protocols. This virtual group is for men and caregivers on or considering AS to treat their condition. New participants are given priority to discuss their situation.
Wednesday evenings of each month at 8 pm EST/EDT (US)
Hi-Risk/Recurrent/Advanced PCa Video Chat, Nov 6, 2023
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Pfizer, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s pick: Several Gents face new lesions, and a couple of GU med oncs overlook the obvious! (rd)
Topics Discussed
Oligometastatic treatment strategies; could this be a recurrence?; single new bone lesion; PSMA shows metastatic lymph node; can prednisone suppress testosterone?; dehydration/low potassium causes brief blackout; full bladder strategies during RT; can you do Provenge while on androgen blockers; GU med onc overlooks PSMA scan; Next Generation Sequencing needed post Pluvicto; AUS coating could be the problem; chemo only works 25% of time
Chat Log
Peter Kafka – Mauisent · 6:33 PM
For some guys it is a question of whether the mets are causing pain or discomfort in deciiding to radiate
For those that have been around AnCan for a while, the name Lindsey Byrne should be familiar. Lindsey is a Genetic Counselor at The Ohio State University (James) Comprehensive Cancer Center who specializes in prostate cancer. Click 
gents, and was a good family friend of another.
